Skip to main content
GDU HEM 2023 Main banner

Full Schedule

  1. Home
  2. Full Schedule

Full Schedule

  • Thursday, June 22, 2023
  • 8:00 AM – 8:15 AM
    Welcome
  • 8:15 AM – 8:50 AM
    8 - Session 8: Exciting Advances in Myelofibrosis

    Presenter: John O. Mascarenhas, MD – Icahn School of Medicine at Mount Sinai

  • 8:50 AM – 9:00 AM
    Live Q&A

    Moderator: Jessica K. Altman, MD – Robert H. Lurie Comprehensive Cancer Center; Northwestern University

    Speaker: John O. Mascarenhas, MD – Icahn School of Medicine at Mount Sinai

  • 9:00 AM – 9:15 AM
    Break
  • 9:15 AM – 9:50 AM
    9 - Session 9: First Line Treatment of CLL/SLL with Bruton 's Tyrosine Kinase Inhibitors: Seeking Lasting Results
  • 9:50 AM – 10:00 AM
    Live Q&A
  • 10:00 AM – 10:15 AM
    Break
  • 10:15 AM – 11:15 AM
    REZLIDHIA: Induce Durable Complete Remissions in Adult Patients with Relapsed/Refractory mIDH1 AML
  • 11:15 AM – 11:30 AM
    Break
  • 11:30 AM – 12:05 PM
    10 - Session 10: What Are the Latest Strategies for Relapsed CLL and What Is on the Horizon?
  • 12:05 PM – 12:15 PM
    10 - Live Q&A
  • 12:15 PM – 12:30 PM
    Break
  • 12:30 PM – 1:15 PM
    Session 11: Where Are We with CAR-T in ALL and AML Today and What Does the Future Look Like?

    Presenter: Jae Park, MD – Memorial Sloan Kettering Cancer Center

  • 1:15 PM – 1:30 PM
    Break
  • 1:30 PM – 2:05 PM
    11 - Session 12: Effective Risk Stratification and Expert Treatment Selection Advice for Patients with Myelodysplastic Syndromes
  • 2:05 PM – 2:15 PM
    Live Q&A
  • 2:15 PM – 2:30 PM
    Break
  • 2:30 PM – 3:15 PM
    12 - Session 13: Case Discussions in AML, MDS and ALL

    Moderator: Jessica K. Altman, MD – Robert H. Lurie Comprehensive Cancer Center; Northwestern University

    Panelist: Shira Dinner, MD – Northwestern University

    Panelist: Amer M. Zeidan, MBBS, MHS – Yale New Haven Health

  • 3:15 PM – 3:30 PM
    Break
  • 3:30 PM – 3:47 PM
    14 - Session 14: Debate - MRD+ Patients with AML Should Proceed with HSCT - Yes
  • 3:47 PM – 4:05 PM
    14 - Session 14: Debate - MRD+ Patients with AML Should Proceed with HSCT - No
  • 4:05 PM – 4:15 PM
    14 - Session 14: Debate - MRD+ Patients with AML Should Proceed with HSCT